About this episode
Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one.
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719
Get every episode summarized
Each time The Evidence Based Rheumatology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Evidence Based Rheumatology Podcast
E133: Obinutuzumab for SLE (ALLEGORY)
The Evidence Based Rheumatology Podcast
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
The Evidence Based Rheumatology Podcast
E131: A Sham-Controlled Sham of a Trial: RESET-RA
The Evidence Based Rheumatology Podcast
E129: Long Term Routine Laboratory Monitoring in RA
The Evidence Based Rheumatology Podcast